Skip to main content

Table 3 Rate and risk of excessive or any blood product transfusion according to antiplatelet drug prescription before coronary artery bypass graft surgery

From: Increased blood product use among coronary artery bypass patients prescribed preoperative aspirin and clopidogrel

Outcome

Antiplatelet drug(s) prescribed

No. (%) with outcome

Crude OR (95% CI)

Adjusted OR (95% CI)**

Excessive transfusion*

Neither

260 (52.4)

1.0

1.0

 

Aspirin alone

58 (55.8)

1.1 (0.8–1.8)

1.0 (0.6–1.6)

 

Clopidogrel alone

6 (54.6)

1.1 (0.3–3.6)

0.7 (0.2–2.5)

 

Aspirin and clopidogrel

33 (71.7)

2.3 (1.2–4.5)

2.2 (1.1–4.3)

Any transfusion

Neither

300 (60.5)

1.0

1.0

 

Aspirin alone

70 (66.7)

1.3 (0.8–2.0)

1.1 (0.7–1.7)

 

Clopidogrel alone

9 (81.8)

3.0 (0.6–13.8)

1.8 (0.4–9.2)

 

Aspirin and clopidogrel

36 (78.3)

2.4 (1.2–4.9)

2.1 (1.0–4.5)

  1. * Defined as a transfusion of ≥ 2 units of non-autologous packed red blood cells, ≥ 2 units of fresh frozen plasma, ≥ 5 units of cryoprecipitate, or ≥ 5 units of platelets, during CABG and up to the second post-operative day. ** Adjusted for age, sex and receipt of 1 or more units of autologous whole blood perioperatively. OR odds ratio; CI confidence interval